Close Menu

NEW YORK – Biomerica said Thursday that it has inked two separate licensing agreements with Mount Sinai’s Icahn School of Medicine in New York for technologies related to a lab-based serological test for SARS-CoV-2.

The technologies, developed at Mount Sinai, are part of a test that uses the ELISA microplate format and can run on open-system equipment located in most US hospitals and clinical laboratories.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.